Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Selection of Clinically Relevant Protease Inhibitor-Resistant Viruses Using the Genotype 2a Hepatitis C Virus Infection System

(2011) Guofeng Cheng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication

(2011) Leen Delang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates

(2011) Amy K Sheaffer et al.   ANTIVIRAL THERAPY

Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections

(2011) Graham R. Foster et al.   GASTROENTEROLOGY

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)

(2011) Ingrid Imhof et al.   HEPATOLOGY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

Future hepatitis C virus treatment: interferon-sparing combinations

(2011) Edward Gane   LIVER INTERNATIONAL

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fast and accurate long-read alignment with Burrows–Wheeler transform

(2010) Heng Li et al.   BIOINFORMATICS

Recombinant HCV Variants With NS5A From Genotypes 1–7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α

(2010) Troels K.H. Scheel et al.   GASTROENTEROLOGY

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice

(2010) Eiji Ohara et al.   JOURNAL OF HEPATOLOGY

Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6

(2010) I. Imhof et al.   JOURNAL OF VIROLOGY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus

(2009) Matthew S. Paulson et al.   ANTIVIRAL RESEARCH

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE